Health care regulation firm Frier Levitt has analyzed FDA enforcement actions from “research only” peptide vendors. Their conclusion: the FDA considers an item’s classification depending on its meant use, not its disclaimers. When Web sites contain dosage guides, reconstitution Recommendations, or l